Skip to main content
. 2011 Aug;72(2):226–234. doi: 10.1111/j.1365-2125.2011.03948.x

Figure 3.

Figure 3

Individual subject steady-state plasma concentrations of 5-hydroxymethyl tolterodine (5-HMT) following administration of fesoterodine (solid and dashed lines for CYP2D6 poor metabolizers and extensive metabolizers respectively; green and blue lines for 4- and 8-mg doses respectively). ER, extended release